Compare UNB & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNB | INDP |
|---|---|---|
| Founded | 1891 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.6M | 125.2M |
| IPO Year | 1999 | 2021 |
| Metric | UNB | INDP |
|---|---|---|
| Price | $23.76 | $1.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.8K | ★ 788.3K |
| Earning Date | 04-15-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.76% | N/A |
| EPS Growth | ★ 25.52 | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.65 | $0.92 |
| 52 Week High | $26.54 | $8.57 |
| Indicator | UNB | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 45.43 | 38.42 |
| Support Level | $23.75 | $0.92 |
| Resistance Level | $24.56 | $2.95 |
| Average True Range (ATR) | 0.40 | 0.17 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 30.00 | 31.06 |
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The Company has one definable business segment, Union Bank, which provides full retail, commercial, municipal banking, and wealth management and trust services throughout its 18 branch banking locations, three loan centers, and several ATMs covering northern Vermont and northern New Hampshire. In addition, it also offers fiduciary and asset management services through its Asset Management Group.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.